drugset / Trial / NCT01416402

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

NCT01416402

Phase 2 Completed 27 enrolled Gilead Sciences
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.

Timeline

Start
2011-08
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Arhalofenate Unknown 600 mg Oral
Background Colchicine Small molecule 0.6 mg Oral
Background Febuxostat Small molecule 80 mg Oral

Indications